U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H32Cl2N2O7
Molecular Weight 567.458
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-4818

SMILES

CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OC[C@@H](O)CN2CCC3(CC4=C(O3)C=CC(Cl)=C4)CC2

InChI

InChIKey=HVTUHSABWJPWNK-SFHVURJKSA-N
InChI=1S/C27H32Cl2N2O7/c1-26(2,25(34)35)37-23-12-22(19(11-20(23)29)24(33)30-3)36-15-18(32)14-31-8-6-27(7-9-31)13-16-10-17(28)4-5-21(16)38-27/h4-5,10-12,18,32H,6-9,13-15H2,1-3H3,(H,30,33)(H,34,35)/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H32Cl2N2O7
Molecular Weight 567.458
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

AZD4818 was developed by AstraZeneca as CCR1 receptor antagonist for the treatment of patients with chronic obstructive pulmonary disease. The study was discontinued, because of a lack of clinical efficacy.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Dry Powder, inhalation, b.i.d., 4 weeks
Route of Administration: Other
Substance Class Chemical
Record UNII
S5UP6P540K
Record Status Validated (UNII)
Record Version